跳至主要内容
临床试验/NCT07572357
NCT07572357招募中不适用

Clinical Evaluation of the RH210 Hearing Aid Software Used With RH210A Device in Adults With Perceived Mild-to-Moderate Hearing Loss

Rehear Audiology Company LTD1 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2026年4月11日最近更新:

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
24
试验地点
1

研究概览

简要总结

The RH210A is an air-conduction hearing aid designed for adults with perceived mild-to-moderate sensorineural hearing loss. The purpose of this clinical investigation is to generate objective and subjective evidence of the clinical performance and safety of the device.

详细描述

The primary objective of this clinical investigation is to demonstrate that the RH210A device provides a clinically meaningful improvement in speech understanding in noise compared with unaided listening in adults with perceived mild-to-moderate hearing loss.

Speech-in-noise performance will be assessed using the BKB-SIN (Australian version), which quantifies the change in signal-to-noise ratio required for sentence recognition. The primary endpoint is defined as the within-subject difference between unaided and RH210 conditions (change in SNR = Unaided - RH210). A successful outcome is defined as a mean improvement of equal to or more than 2 dB in SNR with RH210 compared to unaided listening.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Crossover
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age 18 years
  • Self-perceived mild-to-moderate hearing difficulties/ hearing loss
  • Competent smartphone use (able to complete self-fitting via the app)
  • Able and willing to provide informed consent
  • HHIA screening consistent with perceived hearing difficulty
  • Willingness and ability to attend two in-person research appointments
  • Ability to operate a SmartPhone

排除标准

  • Conductive or mixed hearing loss
  • Occluding cerumen
  • Otologic disease/ active ear pathology
  • Severe or profound hearing loss (PTA >S0dBHL) (WHO, 2021)
  • Presence of (red-flag) conditions relevant to OTC hearing aid use (per 21 CFR 801.421)
  • Visible deformity of the ear (congenital or traumatic).
  • Fluid, pus, or blood coming from the ear (e.g., active drainage).
  • Sudden or rapidly progressive hearing loss within the recent past (often defined as within ~90 days).
  • Any acute or chronic dizziness or vertigo associated with hearing issues.
  • Pain or discomfort in or around the ear.
  • Visible evidence of significant cerumen (ear wax) accumulation or foreign body in the ear canal.
  • Unilateral hearing loss of sudden onset or large asymmetry between ears.
  • Audiometric air-bone gap suggestive of possible conductive pathology (e.g., gap equal or more than 15 dB at key frequencies)
  • Visible evidence of significant cerumen (ear wax) accumulation or foreign body in the ear canal.
  • Unilateral hearing loss of sudden onset or large asymmetry between ears

研究者

发起方
Rehear Audiology Company LTD
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验